A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan

Journal of Clinical Psychopharmacology

Volumn 28, Issue 3, 2008, Pages 271-278

  Gau, Susan Shur Fen ^a,b,d   Chung, Ching Hu ^c   Gau, Churn Shiouh ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b School of Medicine   (Taiwan)

^c Department of Pharmacology ^*  (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZOTEPINE; NEUROLEPTIC AGENT;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; CATATONIC SCHIZOPHRENIA; CONSULTATION; CONTROLLED STUDY; COST OF ILLNESS; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEBEPHRENIA; HOSPITAL COST; HOSPITALIZATION; HUMAN; LATENT SCHIZOPHRENIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MONOTHERAPY; OUTCOME ASSESSMENT; OUTPATIENT; PARANOID SCHIZOPHRENIA; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESIDUAL SCHIZOPHRENIA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIMPLE SCHIZOPHRENIA; TAIWAN; TREATMENT OUTCOME; AMBULATORY CARE; COHORT ANALYSIS; COMPARATIVE STUDY; COST CONTROL; DRUG COMBINATION; DRUG COST; ECONOMICS; LONG TERM CARE; MIDDLE AGED; PATIENT REFERRAL; STATISTICS;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; COST SAVINGS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LONG-TERM CARE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION; SCHIZOPHRENIA; TAIWAN;

EID: 51449113484     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181723713     Document Type: Article

References (36)

1. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics. 2000;18:106-124.
2. Wiersma D, Nienhuis FJ, Slooff CJ, et al. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull. 1998;24:75-85.
3. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia-1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30: 196-205.
4. Gianfrancesco F, Wang RH, Pesa J, et al. Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. Int J Clin Pract. 2006;60:1419-1424.
5. De Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress. J Clin Pharm Ther. 2006;31:523-534.
6. Burton S. Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol. 2006;20:6-19.
7. The Lewin Group. Access and utilization of new antidepressant and antipsychotic medications. Report submitted to the Office of the Assistant Secretary for Planning and Evaluation and the National Institute of Mental Health, US Department of Health and Human Services. January 2000. Available at: http://wwwaspehhsgov/health/ reports/Psychmedaccess. Accessed August 2007.
8. Minas IH, Klimidis S, Stuart GW, et al. Positive and negative symptoms in the psychoses: principal components analysis of items from the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms. Compr Psychiatry. 1994;35:135-144.
9. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
10. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
11. Mojtabai R, Lavelle J, Gibson PJ, et al. Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes. Schizophr Bull. 2003;29:519-530.
12. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand. 2007;115:4-11.
13. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
14. Dossenbach M, Arango-Davila C, Silva Ibarra H, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry. 2005;66:1021-1030.
15. Gianfrancesco F, Rajagopalan K, Wang RH. Hospitalization risks in the treatment of schizophrenia: comparison of antipsychotic medications. J Clin Psychopharmacol. 2006;26:401-404.
16. Rey JA. Antipsychotic therapy: a pharmacoeconomic perspective. Am J Health Syst Pharm. 2002;59:S5-S9.
17. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163: 2080-2089.
18. Brown ES, Thomas NR, Carmody T, et al. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry. 2001;34: 80-81.
19. Coley KC, Carter CS, DaPos SV, et al. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry. 1999;60:850-856.
20. Patel NC, Dorson PG, Edwards N, et al. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv. 2002;53:891-893.
21. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry. 2001;158:266-269.
22. Department of Health, Executive Yuan, Taiwan ROC. Health and National Health Insurance Annual Statistics Information Service Year 2005 and 2006. Available at: http://www.doh.gov.tw/statistic. Accessed August 2, 2007.
23. Chien IC, Chou YJ, Lin CH, et al. Use of health care services and costs of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv. 2004;55:1427-1430.
24. Skrbo A, Begovic B, Skrbo S. Classification of drugs using the ATC system (anatomic, therapeutic, chemical classification) and the latest changes. Med Arh. 2004;58:138-141.
25. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
26. Bellack AS, Gold JM, Buchanan RW. Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. Schizophr Bull. 1999;25:257-274.
27. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002;16:473-484.
28. Knapp M. Costs of schizophrenia. Br J Psychiatry. 1997;171:509-518.
29. Essock SM, Frisman LK, Covell NH, et al. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry. 2000;57:987-994.
30. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67:1542-1550.
31. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006;14:152-164.
32. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006;57:1094-1101.
33. Polsky D, Doshi JA, Bauer MS, et al. Clinical trial-based costeffectiveness analyses of antipsychotic use. Am J Psychiatry. 2006;163: 2047-2056.
34. Buckley PE, Evans D. First-episode schizophrenia. A window of opportunity for optimizing care and outcomes. Postgrad Med. 2006. Spec no: 5-19.
35. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry. 2006;67:E12.
36. DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry. 1998; 59(suppl 19):9-17.